5-Item sino-nasal outcome test and 22-item sino-nasal outcome test relationship with endoscopic and radiologic scores in chronic rhinosinusitis with nasal polyps
- PMID: 37984707
- DOI: 10.1016/j.anai.2023.11.011
5-Item sino-nasal outcome test and 22-item sino-nasal outcome test relationship with endoscopic and radiologic scores in chronic rhinosinusitis with nasal polyps
Abstract
Background: The 22-item sino-nasal outcome test (SNOT-22) is a frequently used patient-recorded outcome measure in patients with chronic rhinosinusitis with nasal polyps (CRSwNPs). Objective findings of nasal polyps and paranasal sinus inflammation are frequently graded using nasal polyp score (NPS) and Lund-Mackay Score (LMS), respectively.
Objective: To evaluate a novel, abbreviated, rhinology-focused, five-domain SNOT-5 questionnaire because we had anecdotally noticed a relative disconnect between SNOT-22 and endoscopy and imaging scores.
Methods: We performed a retrospective, cross-sectional, single-center review of patients with CRSwNPs who had filled out a SNOT-22, along with post hoc-derived SNOT-5 scores, which were then assessed in relation to NPS and LMS.
Results: A total of 129 patients were included in the analysis. SNOT-5 but not SNOT-22 scores significantly correlated vs either NPS (P < .005) and LMS (P < .001), whereas only SNOT-5 differed significantly when comparing the cohort's lowest and highest tertiles for mean LMS: 11.8 vs 16.8 (95% CI, 1.5-8.4; P < .01) and for mean NPS 12.4 vs 15.6 (95% CI, 0.5-5.9; P < .05).
Conclusion: In a retrospective, real-life cohort study of CRSwNP, there was a relative disconnect between the significant association of SNOT-5 but not SNOT-22 in relation to objective endoscopy and imaging measures. We, therefore, propose that further prospective intervention studies are indicated in CRSwNP to evaluate the SNOT-5 score including establishing the minimal clinically important difference.
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosures Mr Misirovs has no relevant conflicts of interest. Dr Chan reports receiving support from AstraZeneca for personal fees (talks) and meeting attendance (European Respiratory Society (ERS)). Dr Lipworth reports receiving support from AstraZeneca for grants (external supported research grant and multicenter trial), meeting attendance (ERS), and personal fees (consulting, talks); support from Chiesi for grants (external supported research grant), meeting attendance (British Thoracic Society), and personal fees (talks); support from Sanofi for grants (external supported research grant); personal fees from Glenmark (consulting, talks); and support from Cipla (consulting). The son of Dr Lipworth is presently an employee of AstraZeneca.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
